期刊文献+

两种方法联合检测基质金属蛋白酶-9在非小细胞肺癌中的表达

下载PDF
导出
摘要 目的:探讨基质金属蛋白酶-9(MMP-9)在非小细胞肺癌(NSCLC)患者血清和癌组织中表达的相关性及临床病理意义。方法:采用ELISA法和免疫组织化学Elivision法,检测82例NSCLC(肺癌组)和20例肺良性病变(对照组)患者手术前后血清MMP-9的水平,及手术切除肺组织标本中MMP-9蛋白的表达。分析血清与癌组织中MMP-9表达的相关性及与临床病理参数之间的关系。结果:(1)肺癌组术前血清MMP-9水平(754.48±133.98)ng/mL明显高于术后(90.78±42.29)ng/mL及对照组(80.43±25.36)ng/mL(P<0.05);(2)肺癌组术前血清MMP-9水平与肿瘤大小、病理类型、TNM分期、淋巴结转移关系密切(P<0.05);(3)MMP-9蛋白在癌组织中的阳性表达率为41.46%,与肿瘤的大小、TNM分期、淋巴结转移有关(P<0.05)。结论:MMP-9在肿瘤浸润和转移中起重要作用,肺癌组血清中MMP-9水平与癌组织中MMP-9蛋白的表达基本一致,血清MMP-9的检测可替代癌组织中的检测。
出处 《实用医学杂志》 CAS 北大核心 2013年第11期1815-1817,共3页 The Journal of Practical Medicine
  • 相关文献

参考文献5

  • 1Egeblad M,Werb Z. New functions for the matrix metalloproteinases in cancer progression [J]. Nat Rev Cancer, 2002,2(3) : 161-17d.
  • 2于萍,步宏,王华,赵高平,张景丽,周桥.免疫组化结果的图像分析与人工计数方法的对比研究[J].生物医学工程学杂志,2003,20(2):288-290. 被引量:186
  • 3Yang E V, Sood A K, Chert M, et al. Norepinephrine up- regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells [J]. Cancer Res, 2006, 66(21 ) : 10357-10364.
  • 4常延河,李迥,张艳敏,刘子洪,郑素芹.MMP-9在人非小细胞肺癌中的表达及其与转移和预后的关系[J].疑难病杂志,2008,7(6):327-329. 被引量:2
  • 5Thomas P, Khokha R, Shepherd F A, et al. Ditferential expression of MMPs and their inhibitors in non-small cell lung cancer[J].J Pathol, 2000, 190(2) : 150-156.

二级参考文献10

  • 1Zeng ZS, Guillem JG. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases[J]. Br J Cancer, 1995,72(3):575-579.
  • 2国际抗癌联盟.肺癌TNM分级定义及分期标准.中华肿瘤杂志,1981,8(1):30-30.
  • 3Mountain CF. Reversions in the intenational system for staging lung cancer [J]. Chest, 1997,111(6) : 1710-1717.
  • 4Coussens LM, Finqleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations[ J]. Science, 2002, 295 (5564) : 2387-2392.
  • 5Jumper C, Cobos E, Los C, Determination of the serum matrix metallopmteinase9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patient with either advanced small-cell lung cancer or nonsmall-cell lung cancer prior to treatment [ J ]. Respir Med, 2004,98 (2) ; 173-177.
  • 6Cox G, Jones JL, O' Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer [J]. Clin Cancer Res,2000,6(6) :2349-2355.
  • 7Bodey B, Bodey Jr, Groger AM, et al. Invasion and metastasis: the expression and significance of matrix metalloproteinases in carcinomas of the lung[J]. In Vivo,2001,15(2) : 175-180.
  • 8Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression [ J ]. Nat Rev Cancer, 2002,2 ( 3 ) : 161 - 174.
  • 9Hoikkala S, PaakkoP, Soinib Y. Tissue MMP-2 and MMP-9 are better prognostic factors than serum MMP-2/TIMP-2-complex or TIMP-1 in stage Ⅰ-Ⅲ lung carcinoma[ J] .Cancer Letter,2006,236(1) : 125-132.
  • 10于萍,步宏,王华,赵高平,张景丽,周桥.免疫组化结果的图像分析与人工计数方法的对比研究[J].生物医学工程学杂志,2003,20(2):288-290. 被引量:186

共引文献186

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部